M
Michele Caraglia
Researcher at Seconda Università degli Studi di Napoli
Publications - 562
Citations - 24508
Michele Caraglia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 67, co-authored 525 publications receiving 20615 citations. Previous affiliations of Michele Caraglia include Temple University & Magna Græcia University.
Papers
More filters
Journal ArticleDOI
Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
Giuseppina Salzano,Monica Marra,M. Porru,Silvia Zappavigna,Alberto Abbruzzese,M.I. La Rotonda,Carlo Leonetti,Michele Caraglia,G. De Rosa +8 more
TL;DR: A significant reduction of tumor growth was achieved with pre-PLCaPZ NPs, while the tumor was unaffected by ZOL in solution, in an animal model of prostate cancer.
Journal ArticleDOI
WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors.
Giuseppe Pannone,Pantaleo Bufo,Angela Santoro,Renato Franco,Gabriella Aquino,Francesco Longo,Gerardo Botti,Rosario Serpico,Barbara Cafarelli,Alberto Abbruzzese,Michele Caraglia,Silvana Papagerakis,Lorenzo Lo Muzio +12 more
TL;DR: It is suggested that a cause of catenin delocalization in oral cancer could be due to WNT pathway activation, by epigenetic alterations of SFRP, WIF-1 and DKK-3 genes.
Journal ArticleDOI
New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study
Monica Marra,Giuseppina Salzano,Carlo Leonetti,Manuela Porru,Renato Franco,Silvia Zappavigna,Giuseppina Liguori,Gerardo Botti,Paolo Chieffi,Monica Lamberti,Giovanni Vitale,Alberto Abbruzzese,Maria Immacolata La Rotonda,Giuseppe De Rosa,Michele Caraglia +14 more
TL;DR: ZOL-containing self-assembly PEGylated nanoparticles (NPs) showed superior technological characteristics in terms of mean diameter, size distribution, and ZOL encapsulation efficiency, compared to LIPO-ZOL, and the anti-cancer activity of NPs in nude mice xenografted with prostate cancer PC3 cells was higher than that one induced by LIP o ZOL.
Journal ArticleDOI
Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR.
Michele Caraglia,Gaia Giuberti,Monica Marra,Raffaele Addeo,Liliana Montella,M. Murolo,Pasquale Sperlongano,Bruno Vincenzi,Silvio Naviglio,S. Del Prete,Alberto Abbruzzese,Paola Stiuso +11 more
TL;DR: The determination of both the oxidative stress status and pERK activity in PBMC has high value in the prediction of response to sorafenib+octreotide therapy in HCC patients.
Journal ArticleDOI
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients
Cirino Botta,Vito Barbieri,Domenico Ciliberto,Antonio Rossi,Danilo Rocco,Raffaele Addeo,Nicoletta Staropoli,Pierpaolo Pastina,Giulia Marvaso,Ignazio Martellucci,Annamaria Guglielmo,Luigi Pirtoli,Pasquale Sperlongano,Cesare Gridelli,Michele Caraglia,Pierfrancesco Tassone,Pierosandro Tagliaferri,Pierpaolo Correale +17 more
TL;DR: A model based on the absence or the presence of at least one of the above-mentioned inflammatory parameters found that the absence of all variables strongly correlated with longer PFS and OS only in NSCLC patients treated with bevacizumab plus chemotherapy.